Ticker > Company >

Alembic Pharma share price

Alembic Pharmaceuticals Ltd.

NSE: APLLTD BSE: 533573 SECTOR: Pharmaceuticals & Drugs  1.78 L   939   156

976.85
-32.50 (-3.22%)
BSE: Today, 04:01 PM

Price Summary

Today's High

₹ 1004.05

Today's Low

₹ 974

52 Week High

₹ 1296.15

52 Week Low

₹ 725.6

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationExpensive
The stock is at a premium valuation at this point.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

19201.27 Cr.

Enterprise Value

20322.65 Cr.

No. of Shares

19.66 Cr.

P/E

38.16

P/B

3.7

Face Value

₹ 2

Div. Yield

1.13 %

Book Value (TTM)

₹  264.28

CASH

20.84 Cr.

DEBT

1142.22 Cr.

Promoter Holding

69.67 %

EPS (TTM)

₹  25.6

Sales Growth

2.7%

ROE

9.96 %

ROCE

11.74%

Profit Growth

-24.51 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Alembic Pharmaceuticals Ltd.

Azithral TELLZY ZEET Elena Corazon MEGACARE ZENOM CORIUM GASTRON ENTERON Maxis Ouron

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year2.7%
3 Year6.21%
5 Year7.86%

Profit Growth

1 Year-24.51%
3 Year-2.54%
5 Year-12.29%

ROE%

1 Year9.96%
3 Year10.47%
5 Year13.56%

ROCE %

1 Year11.74%
3 Year11.19%
5 Year14.14%

Debt/Equity

0.2199

Price to Cash Flow

84.75

Interest Cover Ratio

8.9585

CFO/PAT (5 Yr. Avg.)

1.16059649856483

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 69.67 0.00
Mar 2025 69.67 0.00
Dec 2024 69.61 0.00
Sep 2024 69.61 0.00
Jun 2024 69.61 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • Company has a healthy Interest coverage ratio of 8.9585.
  • The company has an efficient Cash Conversion Cycle of 48.8805 days.
  • The company has a good cash flow management; CFO/PAT stands at 1.16059649856483.
  • The company has a high promoter holding of 69.67%.

 Limitations

  • The company has shown a poor profit growth of -2.54352612661289% for the Past 3 years.
  • The company has shown a poor revenue growth of 6.20801932155517% for the Past 3 years.

Quarterly Result (All Figures in Cr.)

PARTICULARS Mar 2024 Jun 2024 Sep 2024 Dec 2024 Mar 2025
Net Sales 1474.55 1475.56 1580.35 1406.09 1570.64
Total Expenditure 1186.36 1184.13 1320.86 1226.26 1399.98
Operating Profit 288.19 291.43 259.49 179.83 170.66
Other Income 7.22 3.14 16.06 15.46 13.21
Interest 10.13 12.69 18.28 21.79 23.71
Depreciation 69.12 68.68 70.12 69.69 68.6
Exceptional Items 0 0 12.87 0 0
Profit Before Tax 216.16 213.2 200.02 103.81 91.56
Tax 14.29 37.01 34.24 18 16.22
Profit After Tax 201.87 176.19 165.78 85.81 75.34
Adjusted EPS (Rs) 10.27 8.96 8.43 4.37 3.83

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Net Sales 5066.88 5035.4 5149 5874.06 6032.63
Total Expenditure 3617.71 4126.63 4484.97 4876.27 5136.55
Operating Profit 1449.17 908.77 664.03 997.79 896.08
Other Income 84.08 51.17 3.85 32.05 53.19
Interest 12.98 17.02 49 54.47 76.47
Depreciation 182.53 284.92 272.95 271.14 277.08
Exceptional Items 0 0 0 0 12.87
Profit Before Tax 1337.74 658 345.93 704.23 608.59
Tax 241.2 114.45 -0.8 37.75 105.47
Net Profit 1096.54 543.55 346.73 666.48 503.12
Adjusted EPS (Rs.) 55.79 27.65 17.64 33.91 25.6

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Equity and Liabilities
Share Capital 39.31 39.31 39.31 39.31 39.31
Total Reserves 5062.5 5251.03 4374.98 4869.6 5155.43
Borrowings 199.89 0 0 0 0
Other N/C liabilities 203.19 204.25 86.67 83.59 84.51
Current liabilities 1378.36 1694.45 1551.3 1368.4 2285.86
Total Liabilities 6883.25 7189.04 6052.26 6360.9 7565.11
Assets
Net Block 1773.82 1771.1 2377.47 2535.66 2513.47
Capital WIP 1944.28 2205.8 601.28 524.36 837.23
Intangible WIP 238.25 98.44 0 0 0
Investments 156.12 219.36 229.27 226.68 259.56
Loans & Advances 36.4 34.88 64.03 44.46 102.39
Other N/C Assets 0 0 0 0 0
Current Assets 2734.38 2859.46 2780.21 3029.74 3852.46
Total Assets 6883.25 7189.04 6052.26 6360.9 7565.11
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2021 Mar 2022 Mar 2023 Mar 2024 Mar 2025
Profit from operations 1337.74 658.01 345.93 704.23 608.59
Adjustment 92.6 413.35 448.49 284.21 365.07
Changes in Assets & Liabilities 198.56 -397.3 -10.39 -205.64 -701.42
Tax Paid -240.42 -128.8 -53.78 -10.03 -45.67
Operating Cash Flow 1388.48 545.26 730.25 772.77 226.57
Investing Cash Flow -836.65 -368.72 -460.98 -329.02 -636.08
Financing Cash Flow -533.75 -216.64 -261.16 -445.29 403.61
Net Cash Flow 18.08 -40.1 8.11 -1.54 -5.9

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 69.61 69.61 69.61 69.67 69.67
alembic limited 28.54 28.54 28.54 28.54 28.54
barkha pranav amin 0.03 0.03 0.03 0.03 0.03
chirayu ramanbhai amin 2.13 2.13 2.13 2.13 2.13
chirayu ramanbhai amin hu... - - - 0.05 0.05
gallup trust (pranav chir... 0.05 0.05 0.05 0.05 0.05
inaaya shaunak amin 0.04 0.04 0.04 0.04 0.04
krupa shaunak amin 0.03 0.03 0.03 0.03 0.03
malika chirayu amin 1.53 1.53 1.53 1.53 1.53
naintara shaunak amin 0.04 0.04 0.04 0.04 0.04
nirayu limited 35.63 35.63 35.63 35.64 35.64
pranav chirayu amin 0.51 0.51 0.51 0.51 0.51
ranvir pranav amin 0.02 0.02 0.02 0.02 0.02
samira pranav amin 0.02 0.02 0.02 0.02 0.02
satori trust (chirayu ram... 0.03 0.03 0.03 0.03 0.03
shaunak chirayu amin 0.51 0.51 0.51 0.51 0.51
udit chirayu amin 0.51 0.51 0.51 0.51 0.51
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 30.39 30.39 30.39 30.33 30.33
dsp midcap fund 4.20 4.22 4.38 4.60 4.66
investor education and pr... - 0.78 - - 0.78
kotak small cap fund 1.76 1.89 1.77 1.74 1.74
life insurance corporatio... 4.33 4.33 4.32 4.32 4.32
tata aia life insurance c... - - - 1.01 1.15
investor education and pr... 0.73 - 0.78 0.78 -
llp 0.02 0.02 0.02 0.01 -

Annual Reports

Title Link
Title Link
Annual Report 2024
Annual Report 2023
Annual Report 2022
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
Credit CRISIL
Credit CRISIL
Credit CRISIL
Credit CARE
TYPE AGENCY Link
TYPE AGENCY Link
Research BOB Capital Market
Research BOB Capital Market
Research BOB Capital Market
Research Monarch Networth Capital
Research BOB Capital Market
Research Monarch Networth Capital
Research BOB Capital Market
Research ICICI Securities Limited
Research HDFC Securities
Research HDFC Securities
Research ICICI Securities Limited
Research HDFC Securities
Research HDFC Securities
Research Monarch Networth Capital
Research BOB Capital Market
Research BOB Capital Market

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
Concall Q4FY25
Concall Q4FY24
Concall Q4FY22
Concall Q4FY21
Concall Q3FY24
Concall Q3FY22
Concall Q3FY21
Concall Q2FY24
Concall Q2FY22
Concall Q2FY21
Concall Q1FY25
Concall Q1FY24
Concall Q1FY23
Concall Q1FY22
Concall Q1FY21
Concall Q3FY20
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q4FY25
Presentation Q4FY24
Presentation Q4FY20
Presentation Q3FY25
Presentation Q3FY24
Presentation Q3FY21
Presentation Q2FY24
Presentation Q2FY21
Presentation Q1FY25
Presentation Q1FY24
Presentation Q1FY21
Presentation Q3FY20

Company News

Alembic Pharma Stock Price Analysis and Quick Research Report. Is Alembic Pharma an attractive stock to invest in?

The Indian healthcare sector is expected to reach US$ 372 billion by 2022, driven by rising incomes, greater health awareness, lifestyle diseases and increasing access to insurance. Healthcare has become one of India’s largest sectors - both in terms of revenue and employment.

Healthcare comprises hospitals, medical devices, clinical trials, outsourcing, telemedicine, medical tourism, health insurance, and medical equipment. The structure of the healthcare delivery system in India consists of three broad segments: Primary care, Secondary care, and Tertiary care.

  • Primary care is the first point of contact between the population and the healthcare service providers. For example, Sub-center (SC), Primary Health Centre (PHC) and Community Health Centre (CHC) which is more relevant to rural areas (PHC’s).
  • Secondary care providers inpatient as well as outpatient medical services and includes simple surgical procedures. For example, District level & Mid-sized hospitals.
  • Tertiary care is the third level of the healthcare delivery system in the country. These hospitals are specialized consultative healthcare infrastructure. For example, Single specialty and Multi-specialty hospitals.

While healthcare services are offered by the public as well as private sectors, in urban as well as rural areas, generally people prefer private hospitals over public hospitals for treatment of diseases, illness, and sickness. So, let’s look into Alembic Pharma and its performance over the period of time. Alembic Pharma stock price today is Rs 977.9.

  • Operating cash flow ratio: It measures the adequacy of a company’s cash generated from operating activities to pay off short-term financial obligations. Alembic Pharma cash from the operating activity was Rs 226.57 Cr.
     
  • Financial Strength: Health care organizations usually have high debt loads and low equity capital in their balance sheet. So, Debt to Equity ratio is important to analyze the company’s sustainability. Alembic Pharma has a Debt to Equity ratio of 0.2199 , which is a strong indication for the company.
     
  • EPS growth: Investors should ensure the EPS figure is growing faster than revenue numbers because it indicates company management is increasing the efficiency with which it runs the company. In Alembic Pharma , the EPS growth was -24.5107 % which is bad for the company.
     
  • Operating profit margin: It determines a company's potential earnings. It assesses how well-managed a company with respect to its basic overhead costs and other operating expenses, Alembic Pharma has OPM of 14.853886281771 % which is a bad sign for profitability.
     
  • ROE: Alembic Pharma have a poor ROE of 9.9592 %. ROE is an important financial parameter for hospitals & health care companies because they expand and grow rapidly. Therefore, ROE measures how efficiently a shareholder's fund is used for generating profits.
     
  • Share Price: - The current share price of Alembic Pharma is Rs 977.9. One can use valuation calculators of ticker to know if Alembic Pharma share price is undervalued or overvalued.
Last Updated on:
Brief about Alembic Pharma
X